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Abstract 
Purpose 
For visually impaired individuals, motivation to be mobile and the individual’s emotional 
states are predetermining factors of functioning. In addition, loss of confidence at the time of 
diagnosis could inhibit the ability to make progress. The aims of this study are to evaluate 
whether Problem-Solving Treatment (PST), a brief, structured psychological intervention, 
leads to better psychological well-being, in people who have been recently diagnosed as blind 
or partially sighted. 
Methods 
A pilot randomised controlled trial. The trial aims to recruit 120 individuals who have either: 
1) been diagnosed with severe, irreversible sight loss, or 2) registered as blind or partially 
sighted within the last 3 months. Individuals will be randomly allocated to either the 
intervention or control group with randomisation stratified by severity of vision loss. Those in 
the intervention arm will receive PST, an established intervention that addresses individual’s 
confidence, motivation and psychological well-being by undertaking specific tasks to help 
individuals work through their problems, and recognising steps to problem resolution. Both 
groups will continue to receive routine care, such as mobility training.   
Study outcomes 
The primary outcome is psychological well-being measured at 3, 6, and 9 months after 
recruitment and assignment to intervention or control group. Secondary outcomes include 
symptoms of distress, mobility and quality of life. 
 
  
4	  
	  
Background 
Visual impairment is associated with high levels of disability, including loss of mobility and 
reduced ability to perform activities of daily living.1,2 Further, for visually impaired 
individuals, individual motivation to be mobile and their emotional states are predetermining 
factors of functioning.3 The link between vision loss and symptoms of depression is well-
documented.4 Epidemiological data in the UK indicates incidence of depression amongst 
older adults with visual impairment to be 13.5%, compared to 4.6% among older adults with 
normal vision.5 However, major depression is not a normal and expected outcome of vision 
loss in older adults. Most older adults with low vision do not become clinically depressed.4,6 
Instead, throughout the process of losing their vision, older adults may experience distress 
around perceived control, fear of dependency, and perceived loss of ability to maintain 
meaningful personal connections and social roles.7 This may in turn affect motivation and 
confidence to continue with their day-to-day activities, and overall functioning. Hence 
interventions to promote psychological well-being, especially within the early stages after the 
diagnosis of vision loss, are warranted.   
 
Within the UK social care system, those registered as blind or partially sighted are generally 
assessed either by social services or local not for profit organisations to determine the type 
and extent of services required. These typically focus on mobility training, as well as through 
the provision of devices designed to aid activities of daily living such as low vision aids. 
Such rehabilitation services have been shown to be associated with improvements in 
functional status.8 However, these services do not routinely target psychological needs per se, 
and the impact of these services on quality of life (QoL) has been found to be modest.8  
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Several studies have looked at the effectiveness of psychological interventions for vision loss. 
An intervention comprising several components including health education, group discussion, 
and training in behavioural and cognitive skills aimed at reducing barriers to independence, 
was effective in reducing psychological distress and improving self-efficacy in elderly 
individuals with age-related macular degeneration.9 Similarly, a self-management program 
involving health education and cognitive and behavioural training which included training in 
problem solving skills was found to be effective in increasing self-efficacy and reducing 
depressive symptoms at 6 month follow up in people with age-related macular 
degeneration.10 Although in one of the studies9 participants in the intervention group 
increased their use of vision aids, the impact on other aspects of functioning, such as 
mobility, is far from clear.   
 
The Problem-solving Treatment for Visual Impairment trial (POSITIVE) will examine the 
impact of problem-solving treatment (PST),11 on psychological well-being, for newly 
diagnosed visually impaired individuals - approximately 76% of whom are likely to be 65 
years of age or older12. PST is an established intervention which can specifically address 
individuals’ confidence, motivation and psychological well-being.11 It is a brief, structured 
psychological treatment, which focuses on the "here and now" by teaching a rational and 
systematic approach to problem solving and addressing negative perceptions that may 
interfere with finding solutions.11 The behavioural component includes setting specific tasks 
to help individuals work through their problems. The cognitive component demonstrates that 
they need not be overwhelmed by their problems, but that there are practical and effective 
steps to problem resolution. The skills are used to develop practical compensatory strategies 
to achieve valued functional goals thereby promoting better psychological functioning and 
prevention of depression.13  
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PST has been used successfully in people with anxiety and depression within primary 
care.11,14 Interventions based on problem-solving skills training, has been demonstrated in 
various samples (e.g. 15 – 19), including those with macular degeneration.13 PST is likely to be 
an effective tool in coping with the diagnosis of vision loss. Focusing on the present may 
allow individuals to continue managing day-to-day responsibilities, and create situations that 
appear more manageable. PST will offer a clear structure within which to breakdown 
problems into manageable components, establishing achievable goals, and generating 
solutions, with the expectation that their psychological well-being will improve as their 
problems resolve. It has been suggested that PST-treated individuals with macular 
degeneration were able to develop compensatory strategies to continue to pursue valued 
activities, resulting in reduced levels of depression.13 
 
The POSITIVE trial expands upon the research conducted by Rovner and colleagues 13 in 
four primary ways. Firstly, the main aim of the Rovner study was to examine the impact of 
PST in preventing cases of major depression. We are interested in promoting psychological 
well-being, and our primary outcome measure is psychological well-being. In the British 
National Survey of Psychiatric Morbidity at least half of all neurotic disorders were mixed 
anxiety and depressive disorders,20 where the full criteria for major depression and anxiety 
were not met, and there is evidence that this group untreated have persistently lower quality 
of life.21 Especially within the group of people with visual impairment, there are likely to be 
many who do not necessarily meet the clinical criteria for depression, who may nevertheless 
report reduced well-being and may have sub-threshold symptoms of depression or anxiety. 
PST may operate quite differently for prevention of depression in comparison to promotion 
of psychological well-being by raising self-esteem and increasing problem-solving ability in 
the context of newly diagnosed visual impairment. PST may maintain or improve 
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psychological well-being at follow-up in this group of people, and this has yet to be tested.  
Second, our study includes a booster session at 3 months after completion of PST training. 
Rovner and colleagues13 suggest that such booster sessions may prolong the beneficial effects 
of PST, which in their study had diminished by 6-month follow up. Third, we will be 
examining mobility as one of our outcome measures. PST should help individuals to 
recognise the realistic limitations of their visual disabilities, and to come up with alternative 
strategies so that their valued activities can still be performed. The intervention may foster 
the development of problem-solving skills to enable individuals to compensate for their 
mobility through identifying barriers to change for mobility problems, and in-depth solution-
focussed work to overcome these barriers.  Fourth, the population of interest is different. 
While Rovner and colleagues13 and another recent study comparing the efficacy of PST with 
supportive therapy on vision function22 have targeted a group of elderly individuals with age-
related macular degeneration, the present study includes participants from all adult age 
groups with vision loss from all causes. However, we anticipate the majority of participants 
to be older adults. 
Primary objective 
• To determine whether blind and partially sighted people who undertake Problem-
Solving Treatment (PST) demonstrate better psychological well-being (as measured 
by Warwick Edinburgh Mental Well-being Scale), symptoms of distress, mobility and 
quality of life than those undergoing usual care. 
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Secondary objectives 
• To assess the acceptability of PST from the perspective of participants using in-depth 
interviews and qualitative analysis to elicit their experiences of the intervention, and 
aspects that were helpful or unhelpful 
• To evaluate changes in health services resource use  
• To explore  whether changes in self-efficacy and problem-solving ability act as a 
mediator of change in the main outcome measure 
• To explore whether participants’ response to treatment is moderated by the degree of 
vision loss.  
 
Methods/design 
Design 
This trial is a pilot, multicentre, individually randomised controlled trial.  Consenting 
participants who meet the eligibility criteria will be randomised to receive either problem 
solving therapy or care as usual.  The trial design and CONSORT (Consolidating Standards 
of Reporting Trials) flow diagram23 of participants are summarised in Figure 1. 
 
Participants 
Sample size calculations 
Approximately 120 patients will be entered into the study, 60 in the Problem-solving 
Treatment arm and 60 in the control arm.  With this sample size the study will have 80% 
power to detect a statistically significant treatment difference between the groups on the 
Warwick-Edinburgh Mental Well-being Scale at the 5% significance level, assuming a true 
difference of 5 points, a standard deviation of 8.8 (a conservative estimate derived from a 
Scottish population survey24, and a 15% rate of attrition. 
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We aim to recruit for 12 months, equating to a pool of approximately 875 for recruitment 
based on eligible number of people being recently diagnosed within our planned recruitment 
sites. This is a conservative estimate based on approximate number of diagnoses from 
previous years. Estimates suggests around 70% of individuals would fit our eligibility criteria 
(N=612). Previous research13 indicates that only around 50% of individuals will be interested 
in taking part (N=306). Of these, we estimate that only 70% of responders will be eligible for 
the trial, and that a further 10% may drop out at the time of eligibility interviews, which will 
roughly equate to 193 participants who will be eligible for randomisation. The consent rate is 
likely to be around 65%25, allowing for 120 participants required for the trial. 
 
Eligibility criteria 
Inclusion criteria 
Inclusion criteria: adults (≥ 18 years of age); community-dwelling (i.e. not living in a care 
home); and diagnosed with severe, irreversible sight loss, or registered as sight impaired 
(partially sighted) or severely sight impaired (blind) within the previous 3 months.  
 
Exclusion criteria 
Exclusion criteria: participation in psychiatric or psychological assessment or intervention 
within the previous 3 months; have severe cognitive impairment (screened by the Six Item 
Cognitive Impairment Test26; whereby a score of ≥10 will result in exclusion); are severely 
hearing impaired (to a level that makes participation impractical); and/or have insufficient 
proficiency in English to participate. 
 
Sources of participants  
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Participants will be recruited through two methods: 
 
1) Community recruitment via County Council and London Borough Sensory Needs Services 
Information packs containing the Information sheet (both paper and audio copy), a large-font 
reply slip and a pre-paid reply envelope will be sent by the Sensory Needs Service team 
approximately a week after the newly diagnosed individuals receive the Certificate of Visual 
Impairment (CVI).  The Information Sheet will clearly outline the number and duration of 
contact with study personnel in both the intervention and control groups. Those interested in 
participating can contact the Study Coordinator either by phone, or by completing and 
returning the reply slip. Participants will be recruited from 5 Sensory Needs Services across 
South-East England. 
 
2) NHS Eye Hospitals/ Eye Units 
Potential participants will also be identified via 6 NHS Eye Hospitals/Eye Units across 
London, South East and Central England. They will be provided with an Information pack (as 
above) by one of the following: an NHS-based Vision Support Officer (VSO), an 
ophthalmologist, or a research nurse. Individuals are then offered the option of discussing the 
study with the Study Coordinator, with no obligation to participate. If the participant wishes 
to take up the opportunity of the Study Coordinator phoning them, they will be asked to sign 
a sheet indicating permission for their contact details to be passed to the study team. 
 
Telephone screening 
Potential participants will be screened on the telephone to determine whether they meet the 
above inclusion/exclusion criteria. Following telephone screening, the Study Coordinator will 
inform potential participants whether they are eligible to participate in the trial.  The Study 
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Coordinator will then arrange a home visit for eligible participants to talk through and sign 
the consent form, and to complete baseline measures.  At this visit, the Study Coordinator 
will also request access to the participant’s CVI, in order to note the severity and cause of 
visual impairment.  Should a participant not have access to their CVI or a CVI has not been 
issued for the patient, the Study Coordinator will relay the signed consent form to the relevant 
service, which will then release details of cause and severity of visual impairment. 
 
Outcome measures 
Participants in both the problem-solving and control groups will be asked to complete the full 
set of outcome measures at baseline and at 9 months. Outcomes of well-being, symptoms of 
distress, mobility, and quality of life only will additionally be completed at 3 and 6 months in 
order to reduce participant burden so that participants will not be completing measures of 
problem-solving, self-efficacy and health resource use at these time points.   The study 
coordinator will visit participants at their home to conduct baseline outcome measures. 
Subsequent follow-up assessments using the same questionnaires will be conducted over the 
phone. 
 
Main outcomes: 
Our primary outcome measure is psychological well-being, measured by the Warwick-
Edinburgh Mental Well-being Scale (WEMWBS)27.  The WEMWBS is a scale for assessing 
positive mental health (mental well-being), including 14 positively-worded items with five 
response categories. It covers most aspects of positive mental health (positive thoughts and 
feelings) currently in the literature, including both hedonic and eudaimonic perspectives. 
 
Secondary outcomes: 
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Secondary outcomes are as follows: psychological distress, as measured by the Hospital 
Anxiety and Depression Scale28; functional mobility, measured by the Self-assessed 
Instrument for Perceived Visual Ability for Independent Mobility29 and Life Spaces 
Questionnaire30; quality of life, measured by the Impact of Vision Impairment 
Questionnaire31 and the VISQOL32; problem-solving ability, measured by the Social Problem 
Solving Inventory – Revised: Short,33 and self-efficacy, measured by the Generalized Self-
efficacy Scale.34 Self-reported information on health resource use over the previous 4 weeks 
will also be gathered by a health resource use questionnaire developed for a previous study.14   
 
Randomisation  
Randomisation will take place after CVI details have been received. Stratified randomisation 
will be employed to balance severe/moderate vision loss across the intervention/control 
groups.  Blocking will be used within strata with random block sizes.  Participants will be 
randomised using web-based randomisation. In order to ensure the Study Coordinator (who is 
the outcome assessor) is masked to treatment group, participant data (initials, participant 
identification number and level of impairment) will be entered by the study therapist, who 
will then be notified of the randomisation result.  After randomisation the study therapist will 
inform participants as to whether they are in the intervention or control group of the study, 
and will arrange appointments with those allocated to the intervention group.  
 
Trial conditions 
Problem Solving Treatment.   
Six Problem Solving Treatment sessions of 45-60 minutes duration will be conducted over an 
eight week period by a study therapist trained in PST by Dr. Mynors-Wallis, developer of 
PST.  The first 4 sessions will take place weekly, and the last 2 sessions every two weeks. All 
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PST sessions will take place at the participant’s home.  For quality assurance, all PST 
sessions will be digitally recorded. An independent rater will score randomly selected 
sessions for the standard of delivery and any deviations from protocol.  If there are deviations 
to protocol, these will be noted and the extent of any deviations from protocol will be 
reported in any articles or reports presenting the results of the study.   
 
The structure of PST involves a series of seven stages, with core elements of the structure 
present in all sessions.  These stages represent discrete steps in either the treatment process 
(i.e.  explanation of the treatment and its rationale, and evaluation of progress) or in the 
problem-solving process itself (i.e. identifying and defining problems, establishing achievable 
goals, generating solutions, evaluating and choosing the solution and applying the chosen 
solution).35  
 
The first PST session will provide an overview of the problem-solving steps.  Participants 
will then be assisted to identify current problems in their lives and use the problem-solving 
framework to work through solutions to one or two problems in a session, finishing the 
session by agreeing homework tasks to be completed by the second session.  The second and 
subsequent sessions will begin with an evaluation of progress and then follow the problem-
solving structure. In the final session the study therapist will again review problem-solving 
principles and techniques.  The ability of the participants to be effective problem solvers, the 
importance of maintaining a positive orientation, and the usefulness of intervention principles 
as coping tools will be stressed. 
 
Three months after completing the final PST session, the study therapist will conduct a 
follow-up telephone booster session to review knowledge and skills of problem-solving.  A 
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subsample of participants will be interviewed by a researcher using open-ended questions to 
identify aspects of the intervention they found helpful or unhelpful and to identify any 
changes they experienced. This will take place after the 9 months follow-up. 
 
Control group  
Both the intervention and the control group will continue to receive routine medical care 
(such as further eye examinations) and rehabilitation (such as mobility training) depending on 
individual needs, although no psychological intervention will be offered to the control group. 
 
Independent monitoring  
This trial is being conducted with support from PRIMENT UK-CRC Registered Clinical 
Trials Unit36, and will adhere to their Standardised Operating Procedures (SOPs), including 
trial monitoring and quality assurance. A Trial Steering Committee will be established to 
monitor the conduct of the trial.  The committee will meet once every 6 months to monitor 
that the study is being conducted to the standards set out in the Medical Research Council’s 
(MRC) Guidelines for Good Clinical Practice.37 They will assess progress of the trial, 
adherence to protocol, and patient safety. 
 
Quantitative Analysis 
The primary analysis will be a comparison of the primary outcome measure, WEMWBS, 
across treatment groups using an analysis of covariance (ANCOVA) approach via a mixed 
model to adjust for baseline scores and stratification factor and measurements at multiple 
time-points. Analysis will be conducted once the outcome measures have been transformed to 
interval-level measurement using Rasch analysis.38  
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Baseline comparability of the two groups, acceptance of and adherence to treatment, and 
descriptive statistics for all outcome measures will be presented. Analyses will be carried out 
using all randomised patients using the principle of Intention-To-Treat (ITT). Effect sizes 
will be reported with confidence intervals. If sufficient numbers are not collected then only 
descriptive statistics will be presented, rather than p-values. Secondary analyses will adjust 
for covariates including age, gender, cause and degree of visual impairment. Additional 
secondary analyses will explore whether there are any subgroup effects such as between 
those who have severe or moderate/slight vision loss. Supplementary, exploratory analyses 
will be carried out to determine predictors of response to treatment. These will include: 1) 
dichotomous variables e.g. whether the individual has severe or moderate/slight vision loss; 
and 2) continuous variables e.g. scores on baseline questionnaires. Preliminary mediation 
analyses will be conducted to examine self-efficacy as a possible mediator of the treatment 
effect. Further exploratory analyses to examine the extent of vision loss, as a potential 
moderator of response to treatment, will also be conducted. The impact of missing data will 
be investigated via imputation and sensitivity analyses. 
 
Qualitative analysis 
The post session interview data will be analysed using a constant comparative approach.39 
This involves dividing each interview into units, identifying each discrete area through 
extracting significant statements and highlighting of text in the transcripts. The units will then 
be grouped into categories and coded based on similarities and differences. After further 
reflection in comparing and integrating the units, they will be categorised into themes. The 
themes will describe the units of meaning contained within. The clusters of themes will then 
be referred back to the original descriptions for validation. 
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Discussion 
This pilot RCT will establish the feasibility of using PST to improve well-being following a 
diagnosis of visual impairment or severe visual impairment. It will evaluate if those who 
undergo PST demonstrate better outcomes compared to those who undergo ‘care as usual’. 
As we are focusing on the promotion of psychological well-being following a new diagnosis 
of vision loss, our trial has inclusive eligibility criteria. Thus we are offering a psychological 
intervention to a group of people who would not otherwise receive any therapy but are 
nonetheless undergoing significant challenges and may have reduced psychological well-
being and sub-threshold symptoms of depression. We will perform exploratory analyses with 
the results of the present study to explore whether treatment effects depend on baseline values 
of psychological well-being.  
 
This pilot trial will assess whether PST has potential to impact on psychological well-being 
of newly diagnosed people with visual impairment, as well as a number of secondary 
outcomes. It has a relatively long follow-up period (9 months), which will allow for the 
measurement of both the short and long-term effects of the intervention. The inclusion of the 
telephone booster session at 3 months after the completion of the intervention will 
demonstrate whether the PST has sustained impact with fairly minimum costs and resources 
involved for the booster session. By assessing potential mediators of change (self-efficacy 
and problem-solving) with the intervention, the trial can also shed light on the process of 
change in psychological well-being. 
 
The advantages of PST are that it is relatively brief and already well-established. Therefore, if 
found to be an effective therapy, PST could be implemented as part of the usual care package 
provided for people with visual impairment post diagnosis. For example, rehabilitation 
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workers can potentially be trained to deliver PST. Other health care professionals, such as 
nurses who come into contact with newly diagnosed individuals could also potentially be 
trained to deliver PST. Such support would be in line with recommendations from National 
Low Vision Services Consensus Group40 that emotional and practical support should be 
provided within the core rehabilitation service. 
 
PST has the advantage that staff other than mental health specialists can be trained to teach 
problem-solving skills, with evidence that health care professionals such as practice nurses 
can be successfully trained to use PST.41 This contrasts to other psychological interventions, 
such as CBT, where there is negative evidence of its use in routine care by non-mental health 
specialist.42 Thus, compared to other psychological interventions that can only be delivered 
by mental health specialists, there is a wider scope for adoption of PST. PST delivered over a 
few treatment sessions by less highly trained therapists may be advantageous in instances 
when there may be insufficient numbers of mental health specialist therapists, or insufficient 
resources, to provide more intensive treatments to all newly diagnosed people with visual 
impairment.  
 
The trial is set up to be methodologically robust and to conform to best practise for RCTs. 
There is independent web-based randomisation and outcome assessors will be blind to the 
intervention status. Statistical analysis will be conducted using a detailed analysis plan 
developed prior to the first un-blinded data analysis. As an additional check on blinding, the 
study coordinator will record which trial group they think each participant is assigned to, and 
this will be compared to the actual groups to determine if the probability of guessing 
correctly is greater than chance. 
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There will be one study therapist who has been trained by the developer of PST who will 
conduct all the PST sessions, and therapy fidelity will be assessed by an independent rater. 
The outcome measures are self-reported and are collected by the trial coordinator who is 
masked to the randomisation and is not involved in the therapy sessions. Although the control 
group will not receive an intervention, every effort will be made to collect details regarding 
services received (such as rehabilitation services) across all participants. Further, by 
measuring self-reported problem-solving ability in addition to our main outcomes, we can 
explore changes to this ability as an impact of the intervention. The type and frequency of 
services offered to the individuals in each group will be coded, and these will be controlled 
for in our analyses.  
 
Service users have been heavily involved in the study, being consulted for the development 
of the Patient Information Sheets and other materials used in the study as well as being 
present on the Trial Steering Committee. Other advantages of the study include the use of 
qualitative research methods to evaluate the intervention, which again emphasises the views 
of the service users, and will guide us in the best delivery of PST in practice, and in any 
future trials. Another advantage of the trial is the use of Rasch analysis.38 Rasch analysis is 
important because it provides greater insight into the psychometric properties of the 
instrument compared to traditional methods. Several techniques are available to determine 
how well items fit the latent trait being measured; how well the items discriminate between 
the respondents; and how well item difficulty targets person ability.43 Rasch analysis will be 
performed to ensure the validity and reliability of the obtained measures in our sample 
population. 
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Nevertheless, there are challenges to this trial. First, encouraging those who have recently 
been diagnosed as blind or visually impaired to engage in an intervention may be 
challenging. Individuals may feel overwhelmed at this time point, which may limit their 
uptake of services such as PST. Additionally, their vision impairment may make it difficult 
for them to engage in standard methods of information dissemination, such as a participant 
information sheet. For this reason this study has also provided an audio CD version of the 
information sheet. It is hoped this audio CD will encourage a wider number of participants to 
engage with the study. 
 
In conclusion, the POSITIVE pilot trial aims to investigate the impact of PST on the 
psychological well-being of people newly diagnosed with visual impairment, which we 
believe will include a large proportion of older adults. These individuals are not necessarily 
clinically depressed, but nevertheless, face challenges to their daily lives in light of their new 
diagnosis.  
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